BioSpace News Archive

Artios Pharma Limited, a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta inhibitor, ART4215.

Diaprost announced that it has agreed terms for an exclusive Licensing Agreement with Radiopharm Theranostics ; an Australian based biotech startup, focused on building an innovative and differentiated pipeline of radiopharmaceutical products for both diagnostic and therapeutic uses.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following scientific and investor conferences in October:

Pfizer Inc. and BioNTech SE announced they have submitted data to the U.S. Food and Drug Administration from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to <12 years of age.

Cybrexa Therapeutics announced that it will present the results of a preclinical study of CBX-12, the company’s lead therapeutic candidate for solid tumors, at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 7-10, 2021.

Intelivation Technologies, a medical device company with a cutting-edge spinal implant product portfolio announced today the official launch of the Golden Isles Pedicle Screw System™ during the 36th Annual NASS Meeting in Boston September 29-Ocotber 2, 2021.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.

Veeva Systems announced Veeva Vault LIMS, a new cloud application to modernize quality control lab operations.

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

Medtronic plc, the global leader in medical technology, announced it has received CE Mark approval for its radial artery access portfolio, which includes the Rist™ 079 Radial Access Guide Catheter and Rist™ Radial Access Selective Catheter.